Methods for treating lung disorders

Patent metadata

Field	Value
Publication number	US-11160754-B2
Application number	US-201916669692-A
Country	US
Kind code	B2
Filing date	Oct 31, 2019
Priority date	Jun 14, 2017
Publication date	Nov 2, 2021
Grant date	Nov 2, 2021

Abstract

Disclosed herein are compositions and methods for treating lung disorders including lung tumors by pulmonary administration of compositions comprising taxane particles such as docetaxel or paclitaxel particles.

First claim

We claim:

1. A method for treating a lung tumor, comprising pulmonary administration to a subject with a lung tumor of an amount effective of a composition comprising taxane particles to treat the lung tumor, wherein the taxane particles comprise at least 95% of the taxane and have a mean particle size (number) of between 0.1 μm and 5 μm, and wherein the taxane particles have a specific surface area (SSA) of at least 12 m 2 /g.

2. The method of claim 1 , wherein the taxane particles have a mean particle size (number) of between 0.4 μm and 3 μm.

3. The method of claim 1 , wherein the taxane particles have a mean particle size (number) of between about 0.4 μm and about 1.2 μm.

4. The method of claim 1 , wherein the taxane particles have a specific surface area (SSA) of at least 18 m 2 /g.

5. The method of claim 1 , wherein the taxane is present in the suspension at a concentration between about 1 mg/ml and about 40 mg/ml.

6. The method of claim 1 , wherein the taxane particles and suspensions thereof are uncoated and exclude lipids, polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol.

7. The method of claim 1 , wherein the taxane particles are in crystalline form.

8. The method of claim 1 , wherein the taxane particles or a suspension thereof are aerosolized for administration, and the aerosol droplets have a mass median aerodynamic diameter (MMAD) of between about 0.5 μm to about 6 μm diameter.

9. The method of claim 1 , wherein the taxane comprises paclitaxel, docetaxel, cabazitaxel, or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

11. The method of claim 2 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

12. The method of claim 3 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

13. The method of claim 4 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

14. The method of claim 5 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

15. The method of claim 6 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

16. The method of claim 7 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

17. The method of claim 8 , wherein the taxane comprises paclitaxel or a pharmaceutically acceptable salt thereof.

18. The method of claim 1 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

19. The method of claim 2 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

20. The method of claim 3 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

21. The method of claim 4 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

22. The method of claim 5 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

23. The method of claim 6 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

24. The method of claim 7 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

25. The method of claim 8 , wherein the taxane comprises docetaxel or a pharmaceutically acceptable salt thereof.

Assignees

• Crititech Inc

Inventors

• Baltezor Michael
• Mcclorey Matthew
• Johnston William
• Dizerega Gere S
• Verco James

Classifications

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K9/1611

  Inorganic compounds · CPC title

• A61K9/10 Primary

  Dispersions; Emulsions · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61K9/0078 Primary

  for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions · CPC title